688166 博瑞医药
已收盘 12-17 15:00:00
资讯
新帖
简况
12月15日博瑞医药跌6.09%，国泰上证科创板创新药ETF基金重仓该股
证券之星 · 12-15 15:34
12月15日博瑞医药跌6.09%，国泰上证科创板创新药ETF基金重仓该股
每周股票复盘：博瑞医药（688166）将召开Q3业绩说明会
证券之星 · 11-23
每周股票复盘：博瑞医药（688166）将召开Q3业绩说明会
每周股票复盘：博瑞医药（688166）拟5000万增资极客基因
证券之星 · 11-16
每周股票复盘：博瑞医药（688166）拟5000万增资极客基因
博瑞医药（688166）披露关于召开2025年第二次临时股东会的通知，11月14日股价上涨0.85%
证券之星 · 11-14
博瑞医药（688166）披露关于召开2025年第二次临时股东会的通知，11月14日股价上涨0.85%
博瑞医药最新公告：拟5000万元增资参股公司极客基因
证券之星 · 11-14
博瑞医药最新公告：拟5000万元增资参股公司极客基因
博瑞医药递表港交所：估值偏高、业绩走弱、研发掉队、内控问题频发 资本市场是否买单？
新浪证券 · 11-14
博瑞医药递表港交所：估值偏高、业绩走弱、研发掉队、内控问题频发 资本市场是否买单？
博瑞医药(688166.SH)：BGM1812注射液获得药物临床试验批准通知书
智通财经 · 11-13
博瑞医药(688166.SH)：BGM1812注射液获得药物临床试验批准通知书
每周股票复盘：博瑞医药（688166）回购进展披露
证券之星 · 11-09
每周股票复盘：博瑞医药（688166）回购进展披露
博瑞医药（688166）披露股份回购进展公告，11月03日股价上涨1.32%
证券之星 · 11-03
博瑞医药（688166）披露股份回购进展公告，11月03日股价上涨1.32%
每周股票复盘：博瑞医药（688166）股东户数增104.44%，净利降71.64%
证券之星 · 11-02
每周股票复盘：博瑞医药（688166）股东户数增104.44%，净利降71.64%
博瑞医药（688166）披露2025年第三季度报告，10月31日股价上涨7.41%
中金财经 · 10-31
博瑞医药（688166）披露2025年第三季度报告，10月31日股价上涨7.41%
博瑞医药(688166)9月30日股东户数1.96万户，较上期增加104.44%
证券之星 · 10-31
博瑞医药(688166)9月30日股东户数1.96万户，较上期增加104.44%
每周股票复盘：博瑞医药（688166）终止向特定对象发行股票审核
证券之星 · 10-26
每周股票复盘：博瑞医药（688166）终止向特定对象发行股票审核
博瑞医药公布国际专利申请：“GLP-1R/GIPR双激动剂与FGF21化合物组合及用途”
证券之星 · 10-25
博瑞医药公布国际专利申请：“GLP-1R/GIPR双激动剂与FGF21化合物组合及用途”
博瑞医药（688166）披露终止向特定对象发行股票事项，10月20日股价上涨0.53%
证券之星 · 10-20
博瑞医药（688166）披露终止向特定对象发行股票事项，10月20日股价上涨0.53%
博瑞医药（688166）披露拟发行H股并在港交所上市，10月17日股价下跌3.66%
中金财经 · 10-18
博瑞医药（688166）披露拟发行H股并在港交所上市，10月17日股价下跌3.66%
博瑞医药终止5亿元定增，高研发投入背后藏隐忧
新浪证券 · 10-17
博瑞医药终止5亿元定增，高研发投入背后藏隐忧
博瑞医药：终止2024年度向特定对象发行A股股票
视频滚动新闻 · 10-15
博瑞医药：终止2024年度向特定对象发行A股股票
每周股票复盘：博瑞医药（688166）股价跌幅偏离值累计达-50%
证券之星 · 10-12
每周股票复盘：博瑞医药（688166）股价跌幅偏离值累计达-50%
博瑞医药股价腰斩后市盈率仍超240倍，公司紧急提示风险
财中社 · 10-09
博瑞医药股价腰斩后市盈率仍超240倍，公司紧急提示风险
暂无数据
公司概况
公司名称：
博瑞生物医药(苏州)股份有限公司
所属行业：
医药制造业
上市日期：
2019-11-08
主营业务：
博瑞生物医药(苏州)股份有限公司的主营业务是医药中间体、原料药和制剂产品的研发、生产。公司的主要产品是抗病毒、抗真菌、免疫抑制、呼吸系统、抗肿瘤、恩替卡韦、奥司他韦、卡泊芬净、米卡芬净钠。公司先后获得“国家知识产权示范企业”、“国家知识产权优势企业”、“2017年度中国专利优秀奖”、“第十一届中国药学会科学技术奖一等奖”等多项荣誉。
发行价格：
12.71
{"stockData":{"symbol":"688166","market":"SH","secType":"STK","nameCN":"博瑞医药","latestPrice":49.1,"timestamp":1765954800000,"preClose":48.61,"halted":0,"volume":6563472,"delay":0,"changeRate":0.0101,"floatShares":423000000,"shares":423000000,"eps":0.1468,"marketStatus":"已收盘","change":0.49,"latestTime":"12-17 15:00:00","open":48.54,"high":49.35,"low":47.72,"amount":318000000,"amplitude":0.0335,"askPrice":49.11,"askSize":2,"bidPrice":49.1,"bidSize":78,"shortable":0,"etf":0,"ttmEps":0.1468,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766021400000},"marketStatusCode":5,"adr":0,"adjPreClose":48.61,"symbolType":"stock_kcb","openAndCloseTimeList":[[1765935000000,1765942200000],[1765947600000,1765954800000]],"highLimit":53.47,"lowLimit":43.75,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":423102645,"isCdr":false,"pbRate":8.7,"roa":"--","peRate":334.468665,"roe":"2.01%","epsLYR":0.45,"committee":0.323194,"marketValue":20774000000,"turnoverRate":0.0155,"status":0,"afterMarket":{"amount":0,"volume":0,"close":49.1,"buyVolume":0,"sellVolume":0,"time":1765956837768,"indexStatus":"已收盘 12-17 15:30:00","preClose":48.61},"floatMarketCap":20774000000},"requestUrl":"/m/hq/s/688166/tweets","defaultTab":"tweets","newsList":[{"id":"2591615355","title":"12月15日博瑞医药跌6.09%，国泰上证科创板创新药ETF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2591615355","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591615355?lang=zh_cn&edition=full","pubTime":"2025-12-15 15:34","pubTimestamp":1765784071,"startTime":"0","endTime":"0","summary":"证券之星消息，12月15日博瑞医药跌6.09%，收盘报49.94元，换手率3.52%，成交量14.9万手，成交额7.56亿元。重仓博瑞医药的前十大公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共11家，其中持有数量最多的公募基金为国泰基金的国泰上证科创板创新药ETF。国泰上证科创板创新药ETF目前规模为4.26亿元，最新净值0.9383，较上一交易日上涨0.5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500012958.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000300.SH","399001","512880","000001.SH","000905.SH","BK0239","000688.SH","515120","515890","688166","510880","399006","512510","159982","159967","399300","510300"],"gpt_icon":0},{"id":"2585510849","title":"每周股票复盘：博瑞医药（688166）将召开Q3业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2585510849","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585510849?lang=zh_cn&edition=full","pubTime":"2025-11-23 01:39","pubTimestamp":1763833148,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，博瑞医药报收于48.87元，较上周的54.85元下跌10.9%。本周关注点公司公告汇总：博瑞医药将召开2025年第三季度业绩说明会。公司公告汇总博瑞生物医药（苏州）股份有限公司将于2025年12月2日13:00-14:00通过上证路演中心网络文字互动方式召开2025年第三季度业绩说明会，介绍公司2025年第三季度经营成果及财务状况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000255.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"gpt_icon":0},{"id":"2583656944","title":"每周股票复盘：博瑞医药（688166）拟5000万增资极客基因","url":"https://stock-news.laohu8.com/highlight/detail?id=2583656944","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583656944?lang=zh_cn&edition=full","pubTime":"2025-11-16 01:17","pubTimestamp":1763227028,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，博瑞医药报收于54.85元，较上周的53.22元上涨3.06%。本周，博瑞医药11月14日盘中最高价报56.8元。公司公告汇总：博瑞医药拟出资5000万元对苏州极客基因科技有限公司进行增资。公司拟出资5,000万元对苏州极客基因科技有限公司增资，认购其新增注册资本43.7100万元，持股比例由4.0816%增至12.8015%。本次对极客基因的增资构成关联交易，因公司董事长袁建栋担任极客基因董事，且为其关联自然人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000128.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"gpt_icon":0},{"id":"2583504321","title":"博瑞医药（688166）披露关于召开2025年第二次临时股东会的通知，11月14日股价上涨0.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583504321","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583504321?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:12","pubTimestamp":1763129548,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，博瑞医药报收于54.85元，较前一交易日上涨0.85%，最新总市值为232.07亿元。该股当日开盘55.54元，最高56.8元，最低54.22元，成交额达8.15亿元，换手率为3.48%。公司近日发布公告称，将于2025年12月1日召开2025年第二次临时股东会，会议采取现场与网络投票相结合方式，网络投票通过上交所系统进行。股权登记日为2025年11月25日，登记时间2025年11月26日。现场会议地点为苏州工业园区启月街299号独墅湖世尊酒店M9会议室。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400041271.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"gpt_icon":0},{"id":"2583613574","title":"博瑞医药最新公告：拟5000万元增资参股公司极客基因","url":"https://stock-news.laohu8.com/highlight/detail?id=2583613574","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583613574?lang=zh_cn&edition=full","pubTime":"2025-11-14 18:00","pubTimestamp":1763114400,"startTime":"0","endTime":"0","summary":"博瑞医药(688166.SH)公告称，公司拟对苏州极客基因科技有限公司增资5000万元，认缴极客基因新增注册资本43.7100万元，增资后持有极客基因12.8015%股权。公司董事长袁建栋、苏州鸿博创业投资合伙企业（有限合伙）、苏州鸿博二期投资合伙企业（有限合伙）为本轮增资前现有股东，且袁建栋担任极客基因董事。本次交易构成关联交易，未构成重大资产重组。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400029448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166"],"gpt_icon":0},{"id":"2583529354","title":"博瑞医药递表港交所：估值偏高、业绩走弱、研发掉队、内控问题频发 资本市场是否买单？","url":"https://stock-news.laohu8.com/highlight/detail?id=2583529354","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583529354?lang=zh_cn&edition=full","pubTime":"2025-11-14 13:53","pubTimestamp":1763099580,"startTime":"0","endTime":"0","summary":" 近日，博瑞生物医药（苏州）股份有限公司正式向港交所递交招股书，拟于主板挂牌上市。博瑞医药（维权）此次谋求A+H双平台上市，表面理由是加快国际化战略及海外业务布局，但其背后，却是业绩骤降、现金流紧绷、定增告吹后的融资困局。在A股定增终止的背景下，博瑞医药赴港上市被视为缓解资金压力的重要途径，但在估值偏高、业绩走弱、研发掉队、内控问题频发的背景下，资本市场是否会买单，还是未知数。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2025-11-14/doc-infxkanu9178753.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688166","BK0239","HEXmain"],"gpt_icon":0},{"id":"2583548515","title":"博瑞医药(688166.SH)：BGM1812注射液获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2583548515","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583548515?lang=zh_cn&edition=full","pubTime":"2025-11-13 16:13","pubTimestamp":1763021585,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博瑞医药 发布公告，公司全资子公司博瑞制药(苏州)有限公司近日收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意博瑞制药BGM1812注射液开展超重或肥胖的临床试验。BGM1812注射液是公司优化设计的新型长效Amylin类似物，具有良好的分子活性和药学稳定性。截至公告披露日，BGM1812注射液减重适应症在美国已获得FDA的药品临床试验批准，首例临床入组已完成。截至公告披露日，全球尚无同类靶点制剂减重适应症获批上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"博瑞医药(688166.SH)：BGM1812注射液获得药物临床试验批准通知书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688166","BK0239"],"gpt_icon":0},{"id":"2582360866","title":"每周股票复盘：博瑞医药（688166）回购进展披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2582360866","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582360866?lang=zh_cn&edition=full","pubTime":"2025-11-09 01:21","pubTimestamp":1762622469,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，博瑞医药报收于53.22元，较上周的57.4元下跌7.28%。本周，博瑞医药11月3日盘中最高价报58.74元。博瑞医药当前最新总市值225.18亿元，在化学制药板块市值排名23/151，在两市A股市值排名867/5166。本周关注点公司公告汇总：截至2025年10月31日，博瑞医药累计回购股份55,880股，支付资金总额2,993,933.37元。回购进展符合规定，后续将履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900000110.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"gpt_icon":0},{"id":"2580921165","title":"博瑞医药（688166）披露股份回购进展公告，11月03日股价上涨1.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580921165","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580921165?lang=zh_cn&edition=full","pubTime":"2025-11-03 22:22","pubTimestamp":1762179773,"startTime":"0","endTime":"0","summary":"截至2025年11月3日收盘，博瑞医药报收于58.16元，较前一交易日上涨1.32%，最新总市值为246.08亿元。该股当日开盘58.74元，最高58.74元，最低56.66元，成交额达8.32亿元，换手率为3.41%。公司近日发布关于股份回购进展的公告。公告显示，公司于2025年9月26日召开董事会审议通过回购股份方案，拟使用自有资金以集中竞价交易方式回购股份，用于员工持股计划或股权激励。上述回购进展符合相关规定及公司回购方案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300035904.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166"],"gpt_icon":0},{"id":"2580478701","title":"每周股票复盘：博瑞医药（688166）股东户数增104.44%，净利降71.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580478701","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580478701?lang=zh_cn&edition=full","pubTime":"2025-11-02 01:45","pubTimestamp":1762019114,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，博瑞医药报收于57.4元，较上周的53.39元上涨7.51%。本周，博瑞医药10月31日盘中最高价报59.44元。业绩披露要点博瑞医药2025年三季报显示，前三季度主营收入8.74亿元，同比下降10.5%；归母净利润5032.0万元，同比下降71.64%；扣非净利润4617.23万元，同比下降73.41%。公司公告汇总2025年第三季度，公司产品销售收入78,465.38万元，同比减少10.59%；原料药收入67,007.26万元，同比减少8.97%；制剂收入11,458.12万元，同比减少19.02%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200000184.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"gpt_icon":0},{"id":"2579452267","title":"博瑞医药（688166）披露2025年第三季度报告，10月31日股价上涨7.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579452267","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579452267?lang=zh_cn&edition=full","pubTime":"2025-10-31 18:08","pubTimestamp":1761905327,"startTime":"0","endTime":"0","summary":"公司于近日披露了《博瑞生物医药(苏州)股份有限公司2025年第三季度报告》。公告显示，2025年前三季度，公司实现营业收入874,249,705.24元，同比下降10.50%；归属于上市公司股东的净利润为50,320,017.34元，同比下降71.64%；归属于上市公司股东的扣除非经常性损益的净利润为46,172,260.19元，同比下降73.41%。另一创新药BGM1812注射液减重适应症已在美国获得FDA临床试验批准，首例临床入组已完成。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251031/31756566.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688166","BK0239"],"gpt_icon":0},{"id":"2579451590","title":"博瑞医药(688166)9月30日股东户数1.96万户，较上期增加104.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579451590","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579451590?lang=zh_cn&edition=full","pubTime":"2025-10-31 17:33","pubTimestamp":1761903215,"startTime":"0","endTime":"0","summary":"证券之星消息，近日博瑞医药披露，截至2025年9月30日公司股东户数为1.96万户，较6月30日增加9993.0户，增幅为104.44%。在化学制药行业个股中，博瑞医药股东户数低于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.44万户。从股价来看，2025年6月30日至2025年9月30日，博瑞医药区间涨幅为11.34%，在此期间股东户数增加9993.0户，增幅为104.44%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100036837.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166"],"gpt_icon":0},{"id":"2578250092","title":"每周股票复盘：博瑞医药（688166）终止向特定对象发行股票审核","url":"https://stock-news.laohu8.com/highlight/detail?id=2578250092","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578250092?lang=zh_cn&edition=full","pubTime":"2025-10-26 04:35","pubTimestamp":1761424509,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，博瑞医药报收于53.39元，较上周的51.3元上涨4.07%。本周，博瑞医药10月24日盘中最高价报53.86元。公司公告汇总博瑞生物医药（苏州）股份有限公司于2025年10月15日召开第四届董事会第十三次会议，审议通过终止公司2024年度向特定对象发行A股股票事项并撤回申请文件的议案，关联董事袁建栋回避表决。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600001256.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"gpt_icon":0},{"id":"2578440523","title":"博瑞医药公布国际专利申请：“GLP-1R/GIPR双激动剂与FGF21化合物组合及用途”","url":"https://stock-news.laohu8.com/highlight/detail?id=2578440523","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578440523?lang=zh_cn&edition=full","pubTime":"2025-10-25 05:31","pubTimestamp":1761341460,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示博瑞医药（688166）公布了一项国际专利申请，专利名为“GLP-1R/GIPR双激动剂与FGF21化合物组合及用途”，专利申请号为PCT/CN2025/089290，国际公布日为2025年10月23日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来博瑞医药已公布的国际专利申请3个，较去年同期增加了50%。结合公司2025年中报财务数据，今年上半年公司在研发方面投入了1.38亿元，同比减3.14%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102500005032.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166"],"gpt_icon":0},{"id":"2576507038","title":"博瑞医药（688166）披露终止向特定对象发行股票事项，10月20日股价上涨0.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2576507038","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576507038?lang=zh_cn&edition=full","pubTime":"2025-10-20 22:08","pubTimestamp":1760969301,"startTime":"0","endTime":"0","summary":"截至2025年10月20日收盘，博瑞医药报收于51.57元，较前一交易日上涨0.53%，最新总市值为218.19亿元。公告显示，博瑞生物医药（苏州）股份有限公司于2025年10月15日召开第四届董事会第十三次会议，审议通过终止公司2024年度向特定对象发行A股股票事项并撤回申请文件的议案，关联董事袁建栋回避表决。根据相关规定，上交所决定终止对公司向特定对象发行股票的审核。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102000032169.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"gpt_icon":0},{"id":"2576509654","title":"博瑞医药（688166）披露拟发行H股并在港交所上市，10月17日股价下跌3.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2576509654","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576509654?lang=zh_cn&edition=full","pubTime":"2025-10-18 09:40","pubTimestamp":1760751659,"startTime":"0","endTime":"0","summary":"根据公司近日发布的公告，博瑞生物医药(苏州)股份有限公司于2025年10月17日召开2025年第一次临时股东大会，审议通过了关于公司发行H股股票并在香港联合交易所有限公司主板上市的相关议案，包括上市方案、转为境外募集股份有限公司、募集资金使用计划、H股发行前滚存利润分配、审计机构聘任等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251018/31717295.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["HEXmain","688166","BK0239"],"gpt_icon":0},{"id":"2576085942","title":"博瑞医药终止5亿元定增，高研发投入背后藏隐忧","url":"https://stock-news.laohu8.com/highlight/detail?id=2576085942","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576085942?lang=zh_cn&edition=full","pubTime":"2025-10-17 14:35","pubTimestamp":1760682900,"startTime":"0","endTime":"0","summary":"10月16日，博瑞医药（维权）发布公告，宣布终止2024年度向特定对象发行A股股票事项，并撤回相关申请文件。该定增计划原拟募集不超过5亿元资金，用于补充流动资金及偿还银行贷款。公司解释称，此举是“综合考虑当前市场环境、公司实际情况及发展规划”，旨在“保护全体股东利益尤其是中小投资者利益”。 然而，在这份看似稳健的决策背后，博瑞医药正面临多重经营压力与结构性风险，值得市场高度关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2025-10-17/doc-infuetks7207860.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688166"],"gpt_icon":0},{"id":"2575831407","title":"博瑞医药：终止2024年度向特定对象发行A股股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2575831407","media":"视频滚动新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575831407?lang=zh_cn&edition=full","pubTime":"2025-10-15 18:15","pubTimestamp":1760523300,"startTime":"0","endTime":"0","summary":"博瑞医药公告，公司决定终止2024年度向特定对象发行A股股票事项，并向上海证券交易所申请撤回相关文件。此次终止是综合考虑当前市场环境、公司实际情况和发展规划等因素，旨在保护全体股东利益，尤其是中小投资者利益。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：小浪快报","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/videoroll/2025-10-15/doc-inftymnh3483896.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","399300","688166","159982"],"gpt_icon":0},{"id":"2574457476","title":"每周股票复盘：博瑞医药（688166）股价跌幅偏离值累计达-50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2574457476","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574457476?lang=zh_cn&edition=full","pubTime":"2025-10-12 02:00","pubTimestamp":1760205651,"startTime":"0","endTime":"0","summary":"截至2025年10月10日收盘，博瑞医药报收于56.64元，较上周的59.8元下跌5.28%。本周，博瑞医药10月9日盘中最高价报60.47元。本周关注点交易信息汇总：博瑞医药因连续10个交易日收盘价跌幅偏离值累计达-50%登上龙虎榜。预计回购股份数量为7.15万股至14.31万股，占公司总股本比例0.02%至0.03%。博瑞生物医药（苏州）股份有限公司股票连续10个交易日内收盘价格跌幅偏离值累计达到50%，属于股票交易严重异常波动情形。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101200000436.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"gpt_icon":0},{"id":"2574154731","title":"博瑞医药股价腰斩后市盈率仍超240倍，公司紧急提示风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2574154731","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574154731?lang=zh_cn&edition=full","pubTime":"2025-10-09 20:03","pubTimestamp":1760011380,"startTime":"0","endTime":"0","summary":"10月9日，博瑞医药（维权）（688166）发布公告，公司股票连续10个交易日内收盘价格跌幅偏离值累计达到50%。 截至2025年10月9日，公司收盘价为57.57元/股，公司市盈率达243.45倍，显著高于医药制造业30.82倍的行业平均水平，特此提醒投资者注意风险，审慎决策。 2025年中期，博瑞医药实现收入5.37亿元，归母净利润1717万元。（文章来源：财中社）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-09/doc-infticea9587336.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688166"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765999614154,"stockEarnings":[{"period":"1week","weight":-0.0418},{"period":"1month","weight":-0.0805},{"period":"3month","weight":-0.4822},{"period":"6month","weight":-0.1603},{"period":"1year","weight":0.4799},{"period":"ytd","weight":0.6284}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0256},{"period":"3month","weight":0.0101},{"period":"6month","weight":0.1519},{"period":"1year","weight":0.1514},{"period":"ytd","weight":0.1547}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"博瑞生物医药(苏州)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"19561人(较上一季度增加104.44%)","perCapita":"21629股","listingDate":"2019-11-08","address":"江苏省苏州市吴中区工业园区星湖街218号纳米科技园C25栋","registeredCapital":"42310万元","survey":" 博瑞生物医药(苏州)股份有限公司的主营业务是医药中间体、原料药和制剂产品的研发、生产。公司的主要产品是抗病毒、抗真菌、免疫抑制、呼吸系统、抗肿瘤、恩替卡韦、奥司他韦、卡泊芬净、米卡芬净钠。公司先后获得“国家知识产权示范企业”、“国家知识产权优势企业”、“2017年度中国专利优秀奖”、“第十一届中国药学会科学技术奖一等奖”等多项荣誉。","listedPrice":12.71},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博瑞医药(688166)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博瑞医药(688166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博瑞医药,688166,博瑞医药股票,博瑞医药股票老虎,博瑞医药股票老虎国际,博瑞医药行情,博瑞医药股票行情,博瑞医药股价,博瑞医药股市,博瑞医药股票价格,博瑞医药股票交易,博瑞医药股票购买,博瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博瑞医药(688166)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博瑞医药(688166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}